Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) (clinicaltrials.gov) - Oct 9, 2026 - P3 | N=850 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting
Enrollment open • Monotherapy • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|